Binimetinib (MEK162, ARRY-162, ARRY-438162)
Molecular Weight(MW): 441.23
Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Cited by 10 Publications
5 Customer Reviews
Cells seeded in 96-well plates (2,000-3,000 cells per well) were cultured in triplicate with or without graded concentrations of MEK1/2 plus/minus 100 μg/mL cetuximab, which were not renewed during the entire period of cell exposure. For each pair of columns, the height of the left columns represents the sum of the toxic effect of each agent and, therefore, the expected toxicity if their effects were additive when used in combination. The total height of the right columns represents the observed toxicity when the agents were used in combination. The difference between the heights of the paired columns reflects the magnitude of antagonism or synergism on cell toxicity between MEK1/2 inhibitors and cetuximab in NRAS+/+ (left panels) and NRASQ61K/+ (right panels) cells. Results are shown as mean (columns) ± SD (error bars) from at least three experiments in which triplicate wells were analyzed.
Oncotarget, 2016, 7(50):82185-82199. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.
H460 cells were treated with indicated concentration of perifosine (1–3 μM), in the presence or absence of MEK-162 (1 μM) for 48 h, cell apoptosis was tested by either Annexin V FACS assay or histone-DNA apoptosis ELISA assay.
Tumor Biol, 2015, 36: 5699-06. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.
B: ERK and p-ERK1/2 levels in response to MEKi treatment. Tra = trametinib, Ref = refametinib, Sel = selumetinib, Bin = binimetinib. Films were intentionally overexposed to detect signal in lanes with low p-ERK1/2 expression. For each cell line all treatment conditions were performed as part of the same experiment. All experimental findings were confirmed in independent experiments performed in triplicate. Note: membranes incubated with p-ERK1/2 antibody were overexposed to capture all remaining signal after MEKi treatment. WB images have been cut to keep the same sample order. All membranes incubated with the same antibody have been exposed for the same period of time.
Am J Cancer Res, 2016, 6(10):2235-2251. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.
HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).
Biochem Biophys Res Commun, 2016, 474(2):330-7.. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.
Purity & Quality Control
Choose Selective MEK Inhibitors
|Description||Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.|
ARRY-438162 (625 nM) inhibits in vitro osteoclast differentiation with IC50 of 39 nM. ARRY-438162 (10 μM) inhibits in vitro osteoclast resorption with IC50 of 625 nM. ARRY-438162 (2 μM) weakly affects osteoblast differentiation.  ARRY-438162 is a recently disclosed potent and selective ATP non-competitive MEK1/2 inhibitor, inhibits pERK in cells with an IC50 of11 nM.  MEK162 (1 μM) combined with MK-2206 (2 μM) completely reverses the resistance of RSK-expressing MCF7 cells. 
|In vivo||ARRY-438162 (10 mg/kg, po, bid) reduces disease severity in a dose-related manner in rat collagen-induced arthritis (CIA) and rat adjuvant-induced arthritis (AIA) models. ARRY-438162 (po, bid) inhibits increases in ankle diameter by 27% and 50% at 1 mg/kg and 3 mg/kg in the rat collagen-induced arthritis (CIA) model, while ibuprofen has 46% inhibition. ARRY-438162 (10 mg/kg, po, bid) significantly inhibits lesions (inflammation, cartilage damage, pannus formation and bone resorption) by 32% and 60% at 1 mg/kg and 3 mg/kg in the rat collagen-induced arthritis (CIA) model. ARRY-438162 inhibits AIA ankle diameter 11% and 34% at 3 mg/kg and 10 mg/kg in rat adjuvant-induced arthritis (AIA) models.  ARRY-438162 demonstrates dose-related inhibition of ankle swelling in rat adjuvant-induced arthritis (AIA) models, significant at 10 mg/kg and 30 mg/kg when compared to vehicle control. ARRY-438162 demonstrates dose-related inhibition of serum IL-6 concentration in rat adjuvant-induced arthritis (AIA) models, with complete inhibition at 10 mg/kg when compared to vehicle control. ARRY-438162 (30 mg/kg) demonstrates dose-related inhibition of relative spleen weights in rat adjuvant-induced arthritis (AIA) models. ARRY-438162 (30 mg/kg) significantly inhibits bone resorption and inflammation with delayed dosing when compared to vehicle in rat adjuvant-induced arthritis (AIA) models.  MEK162 (6 mg/kg, BID) combined with BEZ235 results in a significant reduction of tumor growth in immunodeficient mice injected with MCF7 cells. |
|In vitro||DMSO||88 mg/mL warmed (199.44 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC+0.5% Tween-80
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03271047||Active not recruiting||MSS|RAS-mutant Colorectal Cancer||Array BioPharma|Bristol-Myers Squibb||October 4 2017||Phase 1|Phase 2|
|NCT03170206||Recruiting||Lung Cancer||Dana-Farber Cancer Institute|Pfizer|Array BioPharma||May 31 2017||Phase 1|Phase 2|
|NCT03231306||Recruiting||Neurofibromatosis Type 1|Plexiform Neurofibroma||University of Alabama at Birmingham|Array BioPharma|Pacific Pediatric Neuro-Oncology Consortium||November 28 2017||Phase 2|
|NCT03106415||Recruiting||Breast Adenocarcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma||Mayo Clinic|National Cancer Institute (NCI)||September 26 2017||Phase 1|Phase 2|
|NCT02902042||Recruiting||Malignant Melanoma||Prof. Dr. med. Dirk Schadendorf|University Hospital Essen||April 24 2018||Phase 1|Phase 2|
|NCT03693170||Not yet recruiting||BRAF V600E-mutant Metastatic Colorectal Cancer||Pierre Fabre Medicament|Array BioPharma|Merck KGaA||October 2018||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
Could please clarify the formulation in vivo for S7007 is clear or not?
S7007 can be dissolved in 5% DMSO+45% PEG 300+ddH2O at 5 mg/ml clearly for injection.